Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:TEVA
DateTimeSourceHeadlineSymbolCompany
05/20/20248:25PMGlobeNewswire Inc.Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.NYSE:TEVATeva Pharmaceutical Industries Ltd
05/20/20248:25PMBusiness WireTeva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.NYSE:TEVATeva Pharmaceutical Industries Ltd
05/15/20248:36AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
05/15/20248:30AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:TEVATeva Pharmaceutical Industries Ltd
05/15/20248:15AMBusiness WireTeva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global OperationsNYSE:TEVATeva Pharmaceutical Industries Ltd
05/09/20247:53AMIH Market NewsBain Capital in Talks to Acquire PowerSchool; Blackstone Emerges Victorious in Hipgnosis Bidding War, and More NewsNYSE:TEVATeva Pharmaceutical Industries Ltd
05/08/20247:00AMBusiness WireTeva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial OutlookNYSE:TEVATeva Pharmaceutical Industries Ltd
05/08/20246:30AMBusiness WireTeva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with SchizophreniaNYSE:TEVATeva Pharmaceutical Industries Ltd
05/02/20246:30PMBusiness WireTeva to Present at the 2024 Bank of America Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
05/02/20248:30AMBusiness WireTeva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious TargetsNYSE:TEVATeva Pharmaceutical Industries Ltd
04/30/20244:00AMBusiness WireU.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)NYSE:TEVATeva Pharmaceutical Industries Ltd
04/30/20244:00AMGlobeNewswire Inc.U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)NYSE:TEVATeva Pharmaceutical Industries Ltd
04/16/20245:43PMBusiness WireAlvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)NYSE:TEVATeva Pharmaceutical Industries Ltd
04/16/20245:30PMGlobeNewswire Inc.Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)NYSE:TEVATeva Pharmaceutical Industries Ltd
04/16/20248:00AMBusiness WireTeva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) TabletsNYSE:TEVATeva Pharmaceutical Industries Ltd
04/11/20248:30AMBusiness WireTeva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in ChinaNYSE:TEVATeva Pharmaceutical Industries Ltd
04/09/20244:30PMBusiness WireTeva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024NYSE:TEVATeva Pharmaceutical Industries Ltd
04/06/20241:00PMBusiness WireNew Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024NYSE:TEVATeva Pharmaceutical Industries Ltd
04/04/20248:30AMBusiness WireTeva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar CandidateNYSE:TEVATeva Pharmaceutical Industries Ltd
04/01/20248:30AMBusiness WireClinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding AgreementNYSE:TEVATeva Pharmaceutical Industries Ltd
03/07/20244:27PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
03/07/20244:24PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
03/07/20244:20PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
03/07/20244:16PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
03/07/20244:12PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
03/07/20244:08PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
03/05/20244:46PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
03/05/20244:43PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
03/05/20244:39PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
03/05/20244:35PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA